NEWS RELEASE

# Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019

2019-11-06

SEATTLE--(BUSINESS WIRE)--Nov. 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

## Conference Call Details

To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 9699377. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 9699377.

To access the live and subsequently archived webcast of the conference call, go to Omeros' website at **www.omeros.com** and select "Events" under the Investors section of the website. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

## About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product **OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%**, Omeros has multiple clinical-stage development programs focused on complement-mediated diseases and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros' proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating platform.

View source version on businesswire.com: **https://www.businesswire.com/news/home/20191106005369/en/**

Source: Omeros Corporation

Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
360.668.3701